Navigation Links
Boston Scientific Announces Schedule for ACC 2008

NATICK, Mass., March 25 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements at the Society for Cardiovascular Angiography and Interventions SCAI Annual Scientific Sessions in Partnership with the American College of Cardiology ACC/i2 Summit, which runs from March 29 to April 1 in Chicago.

"Clinical data presented at ACC for the TAXUS(R) paclitaxel-eluting coronary stent will report on outcomes in a variety of high-risk patient populations," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "We expect results will show continued positive data for the TAXUS Stents in these complex patients and lesions."

Schedule of Events (all times are Central Time)

Saturday, March 29

-- ARRIVE Diabetic Analysis. D. Lynn Morris, M.D., will present one-year

outcomes from a pooled analysis of the ARRIVE 1 & 2 Registries,

including subset data for 4,772 patients, including 1,530 diabetics.

The ARRIVE program is designed to collect and analyze "real-world"

safety and clinical outcomes data for the TAXUS(R) Express2(TM)

paclitaxel-eluting stent system in the treatment of patients with

coronary artery disease. The diabetic sub-group analysis is designed

to evaluate clinical restenosis in diabetic patients and non-diabetics

treated with the TAXUS Express2 Stent. The results will be presented

at 8:00 a.m., during an e-poster session. The Company plans to issue a

press release at this time.

-- ARRIVE High-Risk Patient Analysis. John M. Lasala, M.D., will present

two-year data from 7,307 high-risk patients in the ARRIVE program. The

study is designed to capture long-term safety and effectiveness data of

the TAXUS Express2 Stent in more complex patients treated in routine

practice. The results will be presented at 1:54 p.m., during a

moderated e-poster session. The Company plans to issue a press release

at this time.

Monday, March 31

-- PROMUS(TM) and TAXUS Stents. Results from the Spirit II Clinical Trial

will be presented by Patrick W. Serruys, M.D., PhD, at 8:00 a.m.,

during a Late Breaking Trial session in Grand Ballroom S100. Dr.

Serruys will provide a two-year data analysis of 300 patients treated

with the XIENCE(TM) V (PROMUS) Stent or the TAXUS Express Stent.

SPIRIT II is a randomized, non-inferiority trial designed to obtain CE

Mark approval for both the XIENCE V and PROMUS Stents. The PROMUS

Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent

System manufactured by Abbott and distributed by Boston Scientific.

The Company plans to issue a press release at this time.

PROENCY European Registry

In February, Boston Scientific announced the start of its PROENCY

(PROMUS(TM), ENdeavor(R) and CYpher(R)) European registry, which is

the first of its kind to observe different 'olimus'-eluting coronary

stents. The study will collect real-life clinical outcome data for

Boston Scientific's PROMUS Everolimus-Eluting Stent and compare them

with data from Johnson & Johnson's Cypher(R) Sirolimus-Eluting Stent

and Medtronic's Endeavor(R) Zotarolimus-Eluting Stent in patients

treated in routine clinical practice. Clinical investigators are

currently being recruited for the U.S. phase of PROENCY, which will

begin upon U.S. launch of the PROMUS Stent expected later this year.

-- Biventricular Pacing Percentage in Heart Failure Patients. Bruce

Koplan, M.D., will present a meta-analysis comparing bi-ventricular

pacing percentages and its impact on the combined risk of death and

heart failure hospitalization. The results will be presented at 9:00

a.m., during an oral abstract session in Room S403.

Tuesday, April 1

-- TAXUS Stent in Large Vessels. David A. Cox, M.D., will present an

analysis of data from the TAXUS IV & V randomized clinical trials

comparing the outcomes of drug-eluting stents versus bare-metal stents

in patients with large vessels. The results will be presented at

8:30 a.m., during an oral abstract session in Room S103d.

-- TAXUS IV/V Diabetic data. Gregg W. Stone, M.D., will present

three-year results from a pooled analysis of the TAXUS IV & V clinical

trials, including angiographic and IVUS outcomes at nine months and

clinical outcomes at three years for 317 diabetic patients and 862

non-diabetic patients. The goal of the study is to determine if

diabetes is a risk factor for restenosis and adverse clinical outcomes

in patients treated with the TAXUS Stent. The results will be

presented at 9:31 a.m., during an oral abstract session in Room S103d.

The Company plans to issue a press release at this time.

-- TAXUS Stent TLR meta-analysis. Stephen G. Ellis, M.D., will present a

meta-analysis of long-term follow-up data from more than 1,300 patients

in the TAXUS clinical trial program with up to five years of follow-up.

The study is designed to determine predictors of target lesion

revascularization (TLR) and long-term outcomes in drug-eluting stent

patients who develop in-stent restenosis. The results will be

presented at 9:43 a.m., during an oral abstract session in Room S103d.

The Company plans to issue a press release at this time.

Other TAXUS Stent Data Presentations

-- The following e-poster presentations will highlight additional safety

and efficacy data from Boston Scientific's comprehensive TAXUS clinical

trial program.

-- "Paclitaxel-Eluting Stents Are Effective in Higher Risk Patients:

Gender and Age Specific Sub-Group Analyses of the TAXUS OLYMPIA

Registry" -- (Dr. Oscar Mendiz, et al., moderated e-poster session,

March 29, 8:00 a.m.)

-- "Drug-Eluting Stents and Acute Myocardial Infarction: Experience from

the TAXUS ARRIVE Registry Program" -- (Dr. John Lasala, et al., e-

poster session, March 29, 8:00 a.m.)

-- "Predictors of Stent Thrombosis and Revascularization in Real-World Use

of the TAXUS Express2 Paclitaxel-Eluting Stent: Insights from the

7,300-Patient ARRIVE Program" -- (Dr. John Lasala, et al., moderated e-

poster session, March 29, 2:00 p.m.)

Boston Scientific will present its latest cardiovascular products at booth #18077 in the Exhibit Hall, including its drug-eluting stent and cardiac rhythm management technologies. The booth will also include product and program displays offering physician and patient resources.

TAXUS, Express, Express2 and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott. The SPIRIT Clinical Program is sponsored by Abbott. The PROMUS/XIENCE V Stents are investigational devices and are limited by federal law to investigational use. Premarket Approval (PMA) applications for these stents are currently under review by the U.S. Food and Drug Administration. The PROMUS/XIENCE V Stents are not for sale in the United States or Japan.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth investment. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward- looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Biomedical Research Institute Maintains Baa3 Rating from Moodys
2. Boston College, MIT researchers achieve dramatic increase in thermoelectric efficiency
3. Life Science Industry Awards to Be Announced June 3, 2008 in Boston
4. Evotec to Present at the Cowen and Company 28th Annual Health Care Conference in Boston
5. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
6. Boston Scientific to Participate in Lehman Brothers Health Care Conference
7. Boston Scientific Announces European Approval of New Heart Failure Lead
8. BioSpace Boston Career Fair Attracts over 900 Bioscience Candidates
9. Boston Scientific Announces Addition to Clinical Sciences Organization
10. Boston Scientific Announces Three FDA Product Approvals for Its Cardiac Rhythm Management Business
11. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015  CardioCell LLC, a Stemedica ... cells for cardiovascular indications, intends to proceed with ... on recommendations from a Heart Failure Advisory Board ... Scientific Advisory Board members . In a recent ... IIa safety and efficacy data from CardioCell,s on-going ...
(Date:12/1/2015)... Cepheid (Nasdaq: CPHD ) today announced ... Jaffray Healthcare Conference in New York City ... its outlook for the fourth quarter of 2015 and ... longer term business model expectations. John Bishop ... to be the fastest growing company of the major ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... physicians, aesthetic practitioners and aesthetics professionals from Central America and abroad for the ... in Panama City, Panama Feb. 17-19, 2016. Testart will present and discuss new ...
(Date:11/30/2015)... , Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... it has joined the American Business Act on Climate Pledge, ... that are standing with the Obama Administration to demonstrate an ... a strong outcome to the COP21 Paris ... --> Sarnia, Canada . --> ...
Breaking Biology Technology:
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
Breaking Biology News(10 mins):